ABSI
Absci Corp Health Care Services-Commercial Physical & Biological Research Russell 3000
$11.13Close
$2.30 – $12.1052-week range
Nov 12, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
Cautions
- Results soon Nov 12, 2026, in 11 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
8%
1wk
up 21.2%
price change
1mo
up 3.3%
price change
12-month return
up 172%
market up 11% ·
its own up 144%
F-score
—
— Not assessed
Altman Z″
-1.90
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
down 38%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 63%
return on equity
Free cash margin
down 3358%
-$94.0M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Long-term debt down 100% ($0.0B → $0.0B)
Trade setup
ATR%
8.5%
$0.95 a day · 2×ATR $9.23
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
1.32
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Revenue shrinking Revenue fell 38.2% over the year, from $4.5M to $2.8M.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026+6% vs market2 sessions after results
Financials
- Net -4114%
- Free cash -3358%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $4.8M | $4.8M | $5.7M | $5.7M | $4.5M | $2.8M |
| Operating income | -$13.3M | -$75.2M | -$106.8M | -$115.5M | -$108.9M | -$120.3M |
| Net income | -$14.4M | -$101.0M | -$104.9M | -$110.6M | -$103.1M | -$115.2M |
| Net margin | -300% | -2111% | -1825% | -1934% | -2274% | -4114% |
| Earnings per share | -$0.93 | -$2.03 | -$1.15 | -$1.20 | -$0.94 | -$0.84 |
| Free cash flow | -$13.2M | -$98.6M | -$97.5M | -$65.5M | -$72.8M | -$94.0M |
| Free cash margin | -275% | -2063% | -1697% | -1145% | -1606% | -3358% |
| Cash | $69.9M | $252.6M | $60.0M | $72.4M | $41.2M | $20.0M |
| Long-term debt | $4.1M | $3.5M | $10.9M | $7.9M | $4.0M | $0 |
| Shareholders' equity | -$89.4M | $366.1M | $274.4M | $176.2M | $179.1M | $189.4M |
| Shares outstanding | 17.89m | 92.65m | 92.41m | 93.09m | 115.36m | — |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 24, 2026 | Annual ↗ | Dec 31, 2025 | 83d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 18, 2025 | Annual ↗ | Dec 31, 2024 | 77d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 21, 2024 | Annual ↗ | Dec 31, 2023 | 81d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 11, 2026 | Results · Other events ↗ |
| Jun 24, 2026 | Other events ↗ |
| Jun 24, 2026 | Material agreement · Other events ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results · Other events ↗ |
| Mar 24, 2026 | Results · Other events ↗ |
| Mar 6, 2026 | Material agreement · Director or officer change · Regulation FD ↗ |
| Jan 14, 2026 | Other events ↗ |
| Nov 12, 2025 | Results · Other events ↗ |
| Nov 4, 2025 | Material agreement ↗ |
| Aug 12, 2025 | Results · Other events ↗ |
| Jul 25, 2025 | Material agreement · Other events ↗ |